Acquired Immune Deficiency Syndrome (AIDS)



Evaluating the Safety and Immunogenicity of ALVAC-HIV and MF59®-or AS01B-adjuvanted Bivalent Subtype C gp120 in Healthy, HIV-uninfected Adult Participants


Condition:   HIV Infections
Interventions:   Biological: ALVAC-HIV (vCP2438);   Biological: Bivalent subtype C gp120/MF59;   Biological: Bivalent subtype C gp120/AS01(B);   Biological: Placebo
Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   GlaxoSmithKline;   Sanofi Pasteur, a Sanofi Company
Not yet recruiting - verified April 2017


Randomised Study Comparing Two HIV Screening Strategies


Condition:   HIV Infections
Intervention:   Diagnostic Test: Rapid HIV test
Sponsor:   University of Lausanne Hospitals
Completed - verified January 2017


Safety and Immune Response to a Clade C DNA HIV Vaccine


Condition:   HIV Infections
Interventions:   Biological: DNA-HIV-PT123 vaccine;   Biological: Protein/MF59 vaccine;   Biological: Placebo
Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   HIV Vaccine Trials Network;   IPPOX Foundation;   Novartis Vaccines
Recruiting - verified December 2016


Community-based Distribution of Oral HIV Self-testing Kits


Condition:   HIV Seropositivity
Intervention:   Device: OraQuick® HIV Self-Test (Orasure Technologies, Thailand)
Sponsors:   Zambart;   London School of Hygiene and Tropical Medicine
Not yet recruiting - verified December 2016


Safety and Pharmacokinetic Trial in Healthy HIV-Negative Women to Assess the Delivery of Dapivirine From a Vaginal Ring


Condition:   HIV Infections
Interventions:   Drug: dapivirine;   Drug: placebo
Sponsor:   International Partnership for Microbicides, Inc.
Completed - verified June 2010


VRC-HIVMAB060-00-AB (VRC01) in People With Chronic HIV Infection Undergoing Analytical Treatment Interruption


Condition:   HIV
Intervention:   Biological: VRC-HIVMAB060-00-AB (VRC01)
Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting - verified November 30, 2016


Immune Recovery in Advanced , ARV-naïve, HIV-1-infected Individuals Taking Dolutegravir or Ritonavir-boosted Darunavir


Condition:   Acquired Immune Deficiency Syndrome Virus
Interventions:   Drug: Dolutegravir;   Drug: Darunavir/r
Sponsor:   Juan A. Arnaiz
Recruiting - verified June 2016


Enhancing Linkage to HIV Care for Newly Detected HIV-positive Persons in Ukraine


Condition:   HIV
Intervention:   Behavioral: Modified Antiretroviral Treatment Access Study intervention
Sponsor:   Ukrainian Institute on Public Health Policy
Recruiting - verified April 2017


Metabolomics Fingerprinting and Metabolic Dynamics After HIV Infection


Condition:   HIV
Intervention:  
Sponsor:   Sichuan Academy of Medical Sciences
Recruiting - verified April 2017


Prevention of HIV Infection in High-Risk Social Networks of African American Men Who Have Sex With Men (MSM)


Condition:   HIV
Interventions:   Behavioral: Social Network Intervention;   Behavioral: Counsel, Test, and Treat
Sponsors:   Medical College of Wisconsin;   Mississippi State University;   AIDS Task Force of Greater Cleveland
Active, not recruiting - verified November 2016


Switching From a TDF-Containing Combination Regimen to a TAF-Containing Fixed Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Positive Participants


Conditions:   HIV;   HIV Infections
Interventions:   Drug: E/C/F/TAF;   Drug: E/C/F/TDF;   Drug: EFV/FTC/TDF;   Drug: RTV;   Drug: ATV;   Drug: FTC/TDF;   Drug: COBI
Sponsor:   Gilead Sciences
Active, not recruiting - verified March 2017


Connect to Protect (C2P): Building a Community-Based Infrastructure for HIV Prevention


Condition:   HIV Infection
Intervention:   Behavioral: Community Mobilization
Sponsor:   University of North Carolina, Chapel Hill
Completed - verified May 2016


Antigenic Competition in HIV Preventive Vaccines


Condition:   HIV Infections
Interventions:   Biological: rAd5 Gag-Pol Env A/B/C;   Biological: rAd5 Gag-Pol
Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting - verified September 2016


Validation of a Simple and Cost-Effective Nucleic Acid Test for HIV Detection


Conditions:   HIV;   HIV Infections
Intervention:  
Sponsor:   George Washington University
Completed - verified August 2015


Examining the Role of Genetics in Determining the Immune Response to an HIV Vaccine in HIV-Uninfected Adult Twins


Condition:   HIV Infections
Interventions:   Biological: HIV-1 DNA plasmid vaccine;   Biological: HIV-1 recombinant Ad5 vaccine
Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)
Completed - verified June 2016


Redirected High Affinity Gag‐Specific Autologous T Cells for HIV Gene Therapy


Condition:   HIV Infections
Interventions:   Biological: WT-gag-TCR modified T cells;   Biological: α/6-gag-TCR modified T cells;   Other: STI or Drug Holiday
Sponsors:   University of Pennsylvania;   Adaptimmune
Completed - verified November 2016


Safety of and Immune Response to the PENNVAX-B DNA Vaccine With and Without IL-12 in HIV-uninfected Adults


Condition:   HIV Infections
Interventions:   Biological: PENNVAX-B;   Biological: IL-12 DNA plasmids
Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)
Completed - verified July 2016


Immune Response to an HIV DNA Plasmid Vaccine Prime Followed by Adenovirus Boost in HIV-uninfected Individuals


Condition:   HIV Infections
Interventions:   Biological: VRC-HIVDNA-016-00-VP;   Biological: VRCHIVADV014-00-VP
Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting - verified September 2016


Autologous T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases SB-728 for HIV


Conditions:   HIV;   HIV Infections
Interventions:   Biological: ZFN modified T cells;   Other: Structured Treatment Interruption
Sponsors:   University of Pennsylvania;   Sangamo Therapeutics
Completed - verified November 2016


Safety and Immune Response to a Recombinant Adenovirus HIV-1 Vaccine in Healthy Adults


Condition:   HIV Infections
Intervention:   Biological: Ad5.ENVA.48 HIV-1 vaccine
Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting - verified March 2017


Safety of and Immune Response to an Adenoviral HIV-1 Vaccine in Healthy Adults


Condition:   HIV Infections
Intervention:   Biological: Ad26.ENVA.01 HIV-1 vaccine
Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)
Completed - verified October 2016


Safety of and Immune Response to Two HIV Vaccines: SAAVI DNA-C2 Boosted With SAAVIMVA-C, in HIV-Negative Adults


Condition:   HIV Infections
Interventions:   Biological: SAAVI DNA-C2 vaccine;   Biological: SAAVI MVA-C vaccine;   Biological: Placebo
Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   HIV Vaccine Trials Network
Completed - verified June 2016


Family-based HIV Prevention for Adolescent Girls


Condition:   HIV Infections
Intervention:   Behavioral: Family-Based Risk Reduction Intervention
Sponsors:   University of North Carolina, Chapel Hill;   National Institute on Drug Abuse (NIDA);   National Institute of Mental Health (NIMH);   National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Completed - verified February 2016


Safety of and Immune Response to the Experimental Preventive HIV Vaccine, EP HIV-1090, in Healthy, HIV-1 Uninfected Adults


Condition:   HIV Infections
Interventions:   Biological: EP HIV-1043;   Biological: EP HIV-1090
Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)
Completed - verified June 2016


Preventing Sexual Transmission of HIV With Anti-HIV Drugs


Condition:   HIV Infections
Interventions:   Drug: Atazanavir;   Drug: Didanosine;   Drug: Efavirenz;   Drug: Emtricitabine/Tenofovir disoproxil fumarate;   Drug: Lamivudine;   Drug: Lopinavir/Ritonavir;   Drug: Nevirapine;   Drug: Stavudine;   Drug: Tenofovir disoproxil fumarate;   Drug: Zidovudine/Lamivudine
Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   HIV Prevention Trials Network
Completed - verified November 2016

Refine Your Search Advanced Search